Literature DB >> 27941755

Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis.

Miki Yamaguchi1, Sachie Hirai1, Yusuke Tanaka1,2, Toshiyuki Sumi1,2, Masahiro Miyajima3, Taijiro Mishina3, Gen Yamada2, Mitsuo Otsuka2, Tadashi Hasegawa4, Takashi Kojima5, Toshiro Niki6, Atsushi Watanabe3, Hiroki Takahashi2, Yuji Sakuma1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown cause. IPF has a distinct histopathological pattern of usual interstitial pneumonia in which fibroblastic foci (FF) represent the leading edge of fibrotic destruction of the lung. Currently there are three major hypotheses for how FF are generated: (1) from resident fibroblasts, (2) from bone marrow-derived progenitors of fibroblasts, and (3) from alveolar epithelial cells that have undergone epithelial-mesenchymal transition (EMT). We found that FF dissociated capillary vessels from the alveolar epithelia, the basement membranes of which are fused in normal physiological conditions, and pushed the capillaries and elastic fibers down ~100 μm below the alveolar epithelia. Furthermore, the alveolar epithelial cells covering the FF exhibited a partial EMT phenotype. In addition, normal human alveolar epithelial cells in vitro underwent dynamic EMT in response to transforming growth factor-β signaling within 72 h. Because it seems that resident fibroblasts or bone marrow-derived cells cannot easily infiltrate and form FF between the alveolar epithelia and capillaries in tight contact with each other, FF are more likely to be derived from the epithelial-to-mesenchymal transitioned alveolar epithelia located over them. Moreover, histology and immunohistochemistry suggested that the FF formed in the lung parenchyma disrupt blood flow to the alveolar septa, thus destroying them. Consequently, collapse of the alveolar septa is likely to be the first step toward honeycombing in the lung during late stage IPF. On the basis of these findings, inhibition of transforming growth factor-β signaling, which can suppress EMT of the alveolar epithelial cells in vitro, is a potential strategy for treating IPF.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27941755     DOI: 10.1038/labinvest.2016.135

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

1.  Bronchial epithelium epithelial-mesenchymal plasticity forms aberrant basaloid-like cells in vitro.

Authors:  Dinesh Babu Uthaya Kumar; Efthymios Motakis; Marina Yurieva; Vivek Kohar; Jan Martinek; Te-Chia Wu; Johad Khoury; Jessica Grassmann; Mingyang Lu; Karolina Palucka; Naftali Kaminski; Jonathan L Koff; Adam Williams
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-04-19       Impact factor: 6.011

2.  Tranilast Inhibits Pulmonary Fibrosis by Suppressing TGFβ/SMAD2 Pathway.

Authors:  Motoyasu Kato; Fumiyuki Takahashi; Tadashi Sato; Yoichiro Mitsuishi; Ken Tajima; Hiroaki Ihara; Fariz Nurwidya; Hario Baskoro; Akiko Murakami; Isao Kobayashi; Moulid Hidayat; Naoko Shimada; Shinichi Sasaki; Reiko Mineki; Tsutomu Fujimura; Toshio Kumasaka; Shin-Ichiro Niwa; Kazuhisa Takahashi
Journal:  Drug Des Devel Ther       Date:  2020-10-29       Impact factor: 4.162

3.  The A2B Adenosine Receptor Modulates the Epithelial- Mesenchymal Transition through the Balance of cAMP/PKA and MAPK/ERK Pathway Activation in Human Epithelial Lung Cells.

Authors:  Chiara Giacomelli; Simona Daniele; Chiara Romei; Laura Tavanti; Tommaso Neri; Ilaria Piano; Alessandro Celi; Claudia Martini; Maria L Trincavelli
Journal:  Front Pharmacol       Date:  2018-01-31       Impact factor: 5.810

4.  Epithelial contribution to the profibrotic stiff microenvironment and myofibroblast population in lung fibrosis.

Authors:  Marta Gabasa; Paula Duch; Ignasi Jorba; Alícia Giménez; Roberto Lugo; Irina Pavelescu; Fernando Rodríguez-Pascual; Maria Molina-Molina; Antoni Xaubet; Javier Pereda; Jordi Alcaraz
Journal:  Mol Biol Cell       Date:  2017-10-18       Impact factor: 4.138

5.  Transmembrane protease, serine 4 (TMPRSS4) is upregulated in IPF lungs and increases the fibrotic response in bleomycin-induced lung injury.

Authors:  Ana Valero-Jiménez; Joaquín Zúñiga; José Cisneros; Carina Becerril; Alfonso Salgado; Marco Checa; Ivette Buendía-Roldán; Criselda Mendoza-Milla; Miguel Gaxiola; Annie Pardo; Moisés Selman
Journal:  PLoS One       Date:  2018-03-12       Impact factor: 3.240

6.  Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.

Authors:  Toshiyuki Sumi; Sachie Hirai; Miki Yamaguchi; Yusuke Tanaka; Makoto Tada; Gen Yamada; Tadashi Hasegawa; Yohei Miyagi; Toshiro Niki; Atsushi Watanabe; Hiroki Takahashi; Yuji Sakuma
Journal:  Int J Oncol       Date:  2018-04-11       Impact factor: 5.650

7.  A pre-investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis.

Authors:  Jhon Cores; Phuong-Uyen C Dinh; Taylor Hensley; Kenneth B Adler; Leonard J Lobo; Ke Cheng
Journal:  Stem Cells Transl Med       Date:  2020-04-18       Impact factor: 6.940

8.  Identification and Validation of Potential Biomarkers and Pathways for Idiopathic Pulmonary Fibrosis by Comprehensive Bioinformatics Analysis.

Authors:  Weibin Qian; Xinrui Cai; Qiuhai Qian; Xinying Zhang
Journal:  Biomed Res Int       Date:  2021-07-04       Impact factor: 3.411

9.  PHF8 upregulation contributes to autophagic degradation of E-cadherin, epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.

Authors:  Wuhua Zhou; Li Gong; Qinchuan Wu; Chunyang Xing; Bajin Wei; Tianchi Chen; Yuan Zhou; Shengyong Yin; Bin Jiang; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  J Exp Clin Cancer Res       Date:  2018-09-04

10.  Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma.

Authors:  Miki Yamaguchi; Sachie Hirai; Toshiyuki Sumi; Yusuke Tanaka; Makoto Tada; Yukari Nishii; Tadashi Hasegawa; Hiroaki Uchida; Gen Yamada; Atsushi Watanabe; Hiroki Takahashi; Yuji Sakuma
Journal:  Biochem Biophys Res Commun       Date:  2017-04-20       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.